Kefford RF - Search Results

1

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.

Menzies AM, Haydu LE, Carlino MS, Azer MW, Carr PJ, Kefford RF, Long GV. Menzies AM, et al. Among authors: kefford rf. PLoS One. 2014 Jan 6;9(1):e85004. doi: 10.1371/journal.pone.0085004. eCollection 2014. PLoS One. 2014. PMID: 24400126 Free PMC article.

2

Cutaneous melanoma.

Thompson JF, Scolyer RA, Kefford RF. Thompson JF, et al. Among authors: kefford rf. Lancet. 2005 Feb 19-25;365(9460):687-701. doi: 10.1016/S0140-6736(05)17951-3. Lancet. 2005. PMID: 15721476 Review.

3

Targeting BRAF for patients with melanoma.

Arkenau HT, Kefford R, Long GV. Arkenau HT, et al. Br J Cancer. 2011 Feb 1;104(3):392-8. doi: 10.1038/sj.bjc.6606030. Epub 2010 Dec 7. Br J Cancer. 2011. PMID: 21139585 Free PMC article. Review.

4

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Long GV, et al. Among authors: kefford rf. J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343559

5

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Wilmott JS, et al. Among authors: kefford rf. Clin Cancer Res. 2012 Mar 1;18(5):1386-94. doi: 10.1158/1078-0432.CCR-11-2479. Epub 2011 Dec 12. Clin Cancer Res. 2012. PMID: 22156613

6

Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.

Murali R, Haydu LE, Long GV, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Kefford RF, Thompson JF, Scolyer RA. Murali R, et al. Among authors: kefford rf. Ann Surg Oncol. 2012 Jun;19(6):1782-9. doi: 10.1245/s10434-012-2265-y. Epub 2012 Feb 14. Ann Surg Oncol. 2012. PMID: 22350600 Clinical Trial.

7

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Shi H, et al. Among authors: kefford rf. Nat Commun. 2012 Mar 6;3:724. doi: 10.1038/ncomms1727. Nat Commun. 2012. PMID: 22395615 Free PMC article.

8

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H. Gowrishankar K, et al. Among authors: kefford rf. J Invest Dermatol. 2012 Jul;132(7):1850-9. doi: 10.1038/jid.2012.63. Epub 2012 Mar 22. J Invest Dermatol. 2012. PMID: 22437314 Free article.

9

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Menzies AM, et al. Among authors: kefford rf. Clin Cancer Res. 2012 Jun 15;18(12):3242-9. doi: 10.1158/1078-0432.CCR-12-0052. Epub 2012 Apr 24. Clin Cancer Res. 2012. PMID: 22535154

10

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS. Shi H, et al. Among authors: kefford rf. Cancer Discov. 2012 May;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1. Cancer Discov. 2012. PMID: 22588879 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

298 results

Search Page

Filters